An unconventional FDA panel is assessing the safety and efficacy of previously-banned peptides. It could open up a multibillion-dollar market.

The FDA could decide whether to loosen rules around peptide production this week. Some telehealth players are already seeing dollar signs.

A panel of advisers to the Food and Drug Administration will meet this week to make recommendations on whether specialized pharmacies should be allowed to make some popular…